Conference Reports for NATAP

Back

Tweet

International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs, September 20-22, 2021     Tenofovir alafenamide concentrations are reduced by half in pregnant women living with HIV: data from the PANNA Network. - By Mark Mascolini for NATAP and Virology Education - (09/27/21)   Clinical Application for Coadministration of FTR and HCV medications - (09/22/21)   Special Populations Including End Organ Failure: Focus on Long-Acting Cabotegravir and Rilpivirine - (09/22/21)   Prevalence of clinically significant drug-drug interactions with antiretrovirals against HIV over time: a systematic review of the literature - (09/21/21)   Risk of Low-Level HIV Rises With Each Worse TDF Adherence Level - Mark Mascolini - (09/21/21)   Proposed Fostemsavir Precautions With HCV Meds - Mark Mascolini - (09/21/21)   Dolutegravir Troughs Higher With 3TC, Lower With TAF - Mark Mascolini - (09/21/21)   First 2 Reports of Bictegravir in Pregnancy Suggest Efficacy - Mark Mascolini - (09/21/21)   No Drop in Rate of Drug-Drug & Interactions With HIV Drugs Since 1985 - Mark Mascolini - (09/21/21)   - Mark Mascolini - (09/21/21)   Drug-Drug Interaction Risk High With COVID Meds in Hospital - Mark Mascolini - (09/20/21)   New Oral Ribonucleoside Optimal at 800 mg Twice Daily vs SARS-CoV-2 - Mark Mascolini - (09/20/21)   Phase 1 Trial Suggests Antidiarrheal Nitazoxanide Dose for COVID - Mark Mascolini - (09/20/21)